Survival patterns and mutation profiles in never- and light-smokers with stage IV NSCLC Authors: Kholoud Alqasem, Sakhr Alshwayyat, Salsabeel Aljawabrah, Karam Maraqa, Alaa BanyAmer, Aysheh Al-Khawaja, Bayan Sheikh Ali, Shahed Al-atiyat, Rahaf Turab, Rana Elmalahi, Ala’aldin Eqleem, Sumaiah Alnaimat, Ahmad BanyAmer, Marwa Alshatti, Zaid Omari, Mohammad Abu Shattal Published: 2025 ABSTRACT BackgroundUp to 15% of NSCLC cases arise in never-smokers, and an additional subset arises in light smokers. Data on these groups in the Middle East are limited. Therefore, we compared the clinicopathological features, survival, and molecular alterations in never and light smokers with stage IV NSCLC treated at a tertiary center in Jordan.MethodsWe retrospectively reviewed data from January 2015 to December 2023. Never-smokers were defined as those who had smoked < 100 lifetime cigarettes, and light smokers as those who had smoked < 5 pack-years. Survival rates and prognostic variables were estimated using Kaplan–Meier analysis and univariate Cox models.ResultsAmong 190 patients (median age 54 years), 159 were never smokers and 31 were light smokers. Never smokers were mainly female (69.8%), whereas light smokers were predominantly male (58.1%). Brain metastases were common (55.8%). EGFR mutations occurred in 80.6% of light smokers versus 58.5% of never-smokers. High PD-L1 expression (≥ 50%) was observed in 30% of both groups. One-year OS was 61% in never-smokers and 54.8% in light smokers. EGFR-negative tumors showed better 3- and 5-year OS than EGFR-positive tumors in both smoking strata. No clinical or molecular variables reached statistical significance in the univariate Cox analysis.ConclusionNever and light smokers with stage IV NSCLC displayed distinct features. The high prevalence of actionable EGFR alterations underscores the importance of comprehensive molecular testing. Region-specific data should inform precision oncology strategies and the design of prospective trials targeting non-traditional risk groups.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15333-z. Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, with 2.48 million new cases and 1.82 million deaths reported by 2022 [1]. It continues to impose a significant global disease burden, with projections indicating that by 2050, China will record 1.12 million new cases and 960,000 deaths, whereas the United States will report 170,000 new cases and 110,000 deaths among men [2]. While these numbers show the global impact, they also point to a growing problem in places like the Middle East, making it important to improve early detection and care. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases, making it the most prevalent form of lung malignancy [3]. NSCLC is characterized by a complex genetic landscape that includes driver mutations that influence tumor progression and therapy resistance [4]. Immunotherapy and targeted therapies have revolutionized treatment; however, nearly 50% of patients with NSCLC develop resistance to anti-PD-1 and anti-PD-L1 therapies [5]. The latest NCCN guidelines provide updates based on FDA approvals for molecularly targeted therapies. However, high recurrence rates and distant metastases remain major challenges [6]. Although smoking is the strongest risk factor for NSCLC, 10–15% of cases occur in never-smokers, and a significant subset arises in light smokers [7]. The proportion of never-smokers diagnosed with NSCLC is increasing, particularly among women and younger patients [8]. A population-based study of 41,262 NSCLC cases found that never-smokers were more frequently female (74%) and diagnosed with adenocarcinoma (93%) [8]. Molecular profiling has revealed that EGFR mutations are significantly more common in never-smokers (37%) than in smokers (5%), and ALK rearrangement, ROS1 rearrangement, and BRAF mutations are also enriched in this population [4]. Light smokers remain an understudied NSCLC subgroup, often grouped with ever-smokers, despite the limited data on their tumor biology and treatment response. Most existing research on never and light smokers comes from Western populations, with limited data from the Middle East [9]. This study aimed to address this gap by investigating the clinical characteristics, survival outcomes, and molecular features of never-smokers and light-smokers with stage IV NSCLC in Jordan. To our knowledge, this is the first study to focus on these populations in Jordan, and among the few in the Middle East. By providing region-specific data, our findings contribute to a better understanding of NSCLC in non-traditional risk groups and help guide personalized treatment approaches. Methods This retrospective observational study was conducted at King Hussein Cancer Center (KHCC), a large tertiary cancer center. Our study was approved by the KHCC Institutional Review Board (Proposal NO. 24 KHCC 10), and the requirement for informed consent was waived because of its retrospective nature. Electronic medical records of patients with lung cancer between January 2015 and December 2023 were reviewed. The study population was restricted to patients with histologically confirmed stage IV NSCLC, who were either never-smokers (smoked < 100 cigarettes in their lifetime) or light smokers (smoked < 5 pack-years) [10]. Patients with end-organ failure or missing follow-up data were excluded. Baseline data, including demographic information, tumor characteristics, treatment data, and clinical status, were collected from medical records. Molecular testing for EGFR, ALK, ROS1, and KRAS mutations, as well as PD-L1 expression, was performed in parallel according to institutional protocols. Detailed methodology is provided in Supplementary file 1. ROS1 rearrangement positivity was confirmed by Fluorescence in-situ Hybridization (FISH). Patients who did not undergo molecular analysis, most often due to clinical or socioeconomic constraints, were not excluded from the study. Overall survival (OS) was defined as the time from the first treatment to death or loss to follow-up. Progression-free survival (PFS) was defined as the time from treatment initiation to documented disease progression or death from any cause. Statistical analysis was performed using R software (v4.2.2). Categorical variables were summarized as frequencies and percentages, while continuous variables were reported as means, medians, and standard deviations. Age groups were categorized according to the cohort distribution, with < 46 years corresponding to the first quartile, 46–60 years representing the median range, and > 60 years aligning with the upper quartile. Survival rates were estimated using the Kaplan-Meier method, and comparison of time-to-event outcomes was assessed using the log-rank test. Hazard ratios (HRs) were calculated using the Cox regression analysis. Statistical significance was set at P value of < 0.05. Results Clinicopathological characteristics Among 1471 NSCLC patients diagnosed in KHCC between 2015 and 2023, a total of 190 patients (12.9%) were included in this study. Of these, 178 (93.7%) underwent molecular testing, while 12 (6.3%) had missing molecular data. The median age of the patients was 54 years. Female patients were predominant in the never-smoking group (69.8%), whereas male patients were more common among light smokers (58.1%) (p = 0.01). Overall, 55.8% of the patients presented with brain metastases, with a slightly higher proportion observed in light smokers (64.5%) than in never smokers (54.1%) (p = 0.56). Most patients had ECOG 0–1 (82.1%), while 11.1% had ECOG 2 and 6.8% had ECOG 3–4 (Table 1). Table 1Demographic & clinical characteristicsDemographic & Clinical CharacteristicsLight Smoking(N = 31)Never Smoking(N = 159)Overall(N = 190)P-valueAge < 46 years4 (12.9%)38 (23.9%)42 (22.1%)0.075 > 60 years18 (58.1%)49 (30.8%)67 (35.3%) 46–60 years9 (29.0%)72 (45.3%)81 (42.6%)Sex Female13 (41.9%)111 (69.8%)124 (65.3%)0.012 Male18 (58.1%)48 (30.2%)66 (34.7%)Year of diagnosis 2015–201913 (41.9%)79 (49.7%)92 (48.4%)0.732 2020–202318 (58.1%)80 (50.3%)98 (51.6%)Brain Metastasis at Presentation No11 (35.5%)73 (45.9%)84 (44.2%)0.564 Yes20 (64.5%)86 (54.1%)106 (55.8%)PS. ECOG 0–128 (90.3%)128 (80.5%)156 (82.1%)0.74 22 (6.5%)19 (11.9%)21 (11.1%) 3–41 (3.2%)12 (7.6%)13 (6.8%) Table 1Demographic & clinical characteristicsDemographic & Clinical CharacteristicsLight Smoking(N = 31)Never Smoking(N = 159)Overall(N = 190)P-valueAge < 46 years4 (12.9%)38 (23.9%)42 (22.1%)0.075 > 60 years18 (58.1%)49 (30.8%)67 (35.3%) 46–60 years9 (29.0%)72 (45.3%)81 (42.6%)Sex Female13 (41.9%)111 (69.8%)124 (65.3%)0.012 Male18 (58.1%)48 (30.2%)66 (34.7%)Year of diagnosis 2015–201913 (41.9%)79 (49.7%)92 (48.4%)0.732 2020–202318 (58.1%)80 (50.3%)98 (51.6%)Brain Metastasis at Presentation No11 (35.5%)73 (45.9%)84 (44.2%)0.564 Yes20 (64.5%)86 (54.1%)106 (55.8%)PS. ECOG 0–128 (90.3%)128 (80.5%)156 (82.1%)0.74 22 (6.5%)19 (11.9%)21 (11.1%) 3–41 (3.2%)12 (7.6%)13 (6.8%) Demographic & clinical characteristics Among the light smokers, 80.6% were EGFR-positive compared to 58.5% in the never-smoking group (p = 0.09) (Table 2). Among EGFR-mutant tumors in light smokers Del19 (36%), L858R (28%) and exon20 insertion (4%). In never-smokers Del19 (37.6%), L858R (36.6%), exon20 insertion (2.2%), G719 × (1.1%) and L861Q/G719 × (2.2%). ALK mutations were present in 12.9% of light smokers and 20.1% of never-smokers. ROS1 rearrangement was found in 16.1% of light smokers and 15.7% of never-smokers. Table 2Biomarker & survival characteristicsBiomarker & Survival CharacteristicsLight Smoking(N = 31)Never Smoking(N = 159)Overall(N = 190)P-valueEGFR No5 (16.1%)55 (34.6%)60 (31.6%)0.096 Yes25 (80.6%)93 (58.5%)118 (62.1%) Missing1 (3.2%)11 (6.9%)12 (6.3%)EGFR specific mutation Del 199 (29.0%)35 (22.0%)44 (23.2%)0.996 G719X0 (0%)1 (0.6%)1 (0.5%) INS 201 (3.2%)2 (1.3%)3 (1.6%) L858R7 (22.6%)34 (21.4%)41 (21.6%) L861Q and G719X mutation0 (0%)2 (1.3%)2 (1.1%) Missing14 (45.2%)85 (53.5%)99 (52.1%)ALK No26 (83.9%)116 (73.0%)142 (74.7%)0.588 Yes4 (12.9%)32 (20.1%)36 (18.9%) Missing1 (3.2%)11 (6.9%)12 (6.3%) Missing1 (3.2%)11 (6.9%)12 (6.3%)ROS1 No25 (80.6%)123 (77.4%)148 (77.9%)1 Yes5 (16.1%)25 (15.7%)30 (15.8%) Missing1 (3.2%)11 (6.9%)12 (6.3%)KRAS No30 (96.8%)146 (91.8%)176 (92.6%)0.815 Yes0 (0%)2 (1.3%)2 (1.1%) Missing1 (3.2%)11 (6.9%)12 (6.3%)PDL1/PD1 < 1%5 (16.1%)25 (15.7%)30 (15.8%)0.897 > 49%9 (29.0%)49 (30.8%)58 (30.5%) 1–49%14 (45.2%)48 (30.2%)62 (32.6%) Missing3 (9.7%)37 (23.3%)40 (21.1%)Achieved 1 Year OS No14 (45.2%)62 (39.0%)76 (40.0%)0.814 Yes17 (54.8%)97 (61.0%)114 (60.0%)Achieved 18 Months OS No24 (77.4%)90 (56.6%)114 (60.0%)0.096 Yes7 (22.6%)69 (43.4%)76 (40.0%) Table 2Biomarker & survival characteristicsBiomarker & Survival CharacteristicsLight Smoking(N = 31)Never Smoking(N = 159)Overall(N = 190)P-valueEGFR No5 (16.1%)55 (34.6%)60 (31.6%)0.096 Yes25 (80.6%)93 (58.5%)118 (62.1%) Missing1 (3.2%)11 (6.9%)12 (6.3%)EGFR specific mutation Del 199 (29.0%)35 (22.0%)44 (23.2%)0.996 G719X0 (0%)1 (0.6%)1 (0.5%) INS 201 (3.2%)2 (1.3%)3 (1.6%) L858R7 (22.6%)34 (21.4%)41 (21.6%) L861Q and G719X mutation0 (0%)2 (1.3%)2 (1.1%) Missing14 (45.2%)85 (53.5%)99 (52.1%)ALK No26 (83.9%)116 (73.0%)142 (74.7%)0.588 Yes4 (12.9%)32 (20.1%)36 (18.9%) Missing1 (3.2%)11 (6.9%)12 (6.3%) Missing1 (3.2%)11 (6.9%)12 (6.3%)ROS1 No25 (80.6%)123 (77.4%)148 (77.9%)1 Yes5 (16.1%)25 (15.7%)30 (15.8%) Missing1 (3.2%)11 (6.9%)12 (6.3%)KRAS No30 (96.8%)146 (91.8%)176 (92.6%)0.815 Yes0 (0%)2 (1.3%)2 (1.1%) Missing1 (3.2%)11 (6.9%)12 (6.3%)PDL1/PD1 < 1%5 (16.1%)25 (15.7%)30 (15.8%)0.897 > 49%9 (29.0%)49 (30.8%)58 (30.5%) 1–49%14 (45.2%)48 (30.2%)62 (32.6%) Missing3 (9.7%)37 (23.3%)40 (21.1%)Achieved 1 Year OS No14 (45.2%)62 (39.0%)76 (40.0%)0.814 Yes17 (54.8%)97 (61.0%)114 (60.0%)Achieved 18 Months OS No24 (77.4%)90 (56.6%)114 (60.0%)0.096 Yes7 (22.6%)69 (43.4%)76 (40.0%) Biomarker & survival characteristics PD-L1 expression levels were not significantly different between groups. High PD-L1 expression (> 49%) was observed in 29% of light smokers and 30.8% of never smokers (p = 0.89). KRAS mutations were rare, with only two cases in the never-smoking group (Table 2). Survival analysis One-year OS was achieved in 54.8% of light smokers and 61% of never smokers (p = 0.81). Similarly, an 18-month OS was achieved in 22.6% of light smokers and 43.4% of never smokers (p = 0.09). The median OS for the entire cohort was 15.52 months. The survival rates for different years are presented in Supplementary Tables 1 and 2. Among patients ≤ 46 years, light smokers experienced 100% OS at 1, 3, and 5 years, compared with 67.1%, 29.2%, and 29.2% in never smokers (Figs. 1 and 2). However, none of the light smokers in this age group remained progression-free after 1 year, whereas 48.8% of never-smokers did. In the ≥ 60-year cohort, the 5-year OS dropped to 0% for light smokers versus 14.4% for never-smokers, and the 5-year PFS was 0% in light smokers and 7.5% in never smokers. Fig. 1Kaplan–Meier curves in light smokers stratified by age and sex. Panels show overall survival by age (A), progression-free survival by age (B), overall survival by sex (C), and progression-free survival by sex (D) Kaplan–Meier curves in light smokers stratified by age and sex. Panels show overall survival by age (A), progression-free survival by age (B), overall survival by sex (C), and progression-free survival by sex (D) Fig. 2Kaplan–Meier curves in never-smokers stratified by age and sex. Panels show overall survival by age (A), progression-free survival by age (B), overall survival by sex (C), and progression-free survival by sex (D) Kaplan–Meier curves in never-smokers stratified by age and sex. Panels show overall survival by age (A), progression-free survival by age (B), overall survival by sex (C), and progression-free survival by sex (D) Sex-based differences were also observed. Female light smokers had a 1-year OS of 92.3% versus 74.8% in never-smoking females, yet neither group had survivors at 5 years (Figs. 1 and 2). Among males, never-smokers had slightly better in early OS (58.5% vs. 57.2% at 1 year; 27.5% vs. 19.6% at 3 years), but light smokers had a marginally higher 5-year OS (19.6% vs. 17.7%). Male light smokers had no PFS beyond the first year, whereas never-smoking males had 34.7% PFS at the first year. The ECOG performance status and year of diagnosis highlighted the influence of functional status and advances in care. In ECOG 0 patients, 1-year OS was 86.7% for light smokers and 78.3% for never-smokers, but only never-smokers (30.1%) survived for 5 years. The PFS at 1 year favored never-smokers (54.6% vs. 31.1% in light smokers), with no light smokers remaining progression-free beyond 3 years (Supplementary Figs. 1 and 2). Diagnosis in the more recent period (2020–2023) was associated with markedly improved outcomes. Light smokers diagnosed then had 94.1% 1-year OS and 29.6% 5-year OS, compared with 44% and 11% for those diagnosed in 2015–2019. Among light smokers, EGFR-negative patients showed relatively favorable OS, with rates of 80.0% at 1 year, declining to 30.0% at both 3 and 5 years, while their PFS remained stable at 25.0% across all time points (Figs. 3 and 4). In contrast, EGFR-positive light smokers had poorer outcomes, with OS decreasing from 69.4% at 1 year to 24.9% at 3 years and 0% at 5 years, and PFS decreasing to 0% by 3 years. Among never-smokers, EGFR-negative individuals had OS rates of 72.8%, 36.5%, and 36.5% at 1, 3, and 5 years, respectively, with PFS declining from 59.1% at 1 year to 0% at 5 years. EGFR-positive never-smokers showed an OS of 71.1% and 32.2% at 3 years and 10.6% at 1, 3, and 5 years, respectively, while their PFS dropped to 5.0% at 5 years. Fig. 3Kaplan–Meier curves in light smokers stratified by brain metastasis and EGFR mutation status. Panels show overall survival by brain metastasis (A), progression-free survival by brain metastasis (B), overall survival by EGFR mutation status (C), and progression-free survival by EGFR mutation status (D) Kaplan–Meier curves in light smokers stratified by brain metastasis and EGFR mutation status. Panels show overall survival by brain metastasis (A), progression-free survival by brain metastasis (B), overall survival by EGFR mutation status (C), and progression-free survival by EGFR mutation status (D) Fig. 4Kaplan–Meier curves in never-smokers stratified by brain metastasis and EGFR mutation status. Panels show overall survival by brain metastasis (A), progression-free survival by brain metastasis (B), overall survival by EGFR mutation status (C), and progression-free survival by EGFR mutation status (D) Kaplan–Meier curves in never-smokers stratified by brain metastasis and EGFR mutation status. Panels show overall survival by brain metastasis (A), progression-free survival by brain metastasis (B), overall survival by EGFR mutation status (C), and progression-free survival by EGFR mutation status (D) Regarding brain metastasis status, light smokers with brain metastases had worse survival, with OS declining from 72.6% at 1 year to 10.2% at both 3 and 5 years, and PFS remaining at 8.6% after 3 years (Figs. 3 and 4). Conversely, light smokers without brain metastases showed higher OS, with 71.6% and 53.7% at 3 years, and 26.9% at 1, 3, and 5 years, respectively, although PFS remained at 9.1% throughout. Among never-smokers, patients with brain metastases had OS rates of 66.4%, 31.8%, and 20.5% at 1, 3, and 5 years, respectively, with PFS declining to 2.8% at 5 years. Never-smokers without brain metastases had OS rates of 73.9%, 29.1%, and 17.0% across the same time points, with PFS decreasing to 6.3% at 5 years. Treatment response For first line therapy 112 patients received first-generation EGFR tyrosine kinase inhibitor (gefitinib), 31 received chemotherapy, 29 received ALK inhibitor, 7 received immunotherapy, 6 received ROS1 inhibitors and 5 received chemotherapy with immunotherapy. Patients who received ROS1, ALK or EGFR TKIs demonstrated better OS and PFS in comparison to standard chemotherapy, immunotherapy or immunochemotherapy regimens (Supplementary Tables 4–5, Supplementary Figs. 3). Interestingly, 34/112 (30.4%) of the patients who received gefitinib developed T790M mutation. Prognostic factors To identify potential independent prognostic factors, univariate Cox regression analyses were conducted separately for never-smokers and light smokers. None of the evaluated variables were significantly associated with OS or PFS in either group (Supplementary Table 4). Therefore, multivariate analysis was not performed. Discussion Despite the well-established links between smoking and NSCLC, emerging data suggests distinct clinical and molecular patterns in never- and light-smoking populations, raising important questions regarding prognosis and treatment responses. Our study examined these differences in a Middle Eastern cohort, providing new insights into survival outcomes and genetic profiles that may help refine treatment strategies. The incidence of non-smoking NSCLC in our cohort was 12.9%, closely aligning with a 2021 U.S. study reporting a 12.5% incidence in non-smoking lung cancer patients [11]. However, the incidence in our study is lower than in neighboring Saudi Arabia and other Gulf countries, where rates range from around 20.8% in Bahrain to around 28.1% in Saudi Arabia, likely reflecting the differences in defining “non-smokers” and adherence to these definitions across studies [12, 13]. Moreover, the high documented smoking rates and second-hand smoke exposure among Jordanians suggest that smoking remains a major contributor to lung cancer, with only a small portion being attributed to other biological disturbances. National reports indicate that around 60% of cancer patients are treated at KHCC, supporting the representativeness of our cohort in the Jordanian population. A prospective study by Wallace et al. (2024), involving 265 patients with stage III NSCLC treated with concurrent chemoradiotherapy, reported a median OS of 5.5 years for never-smokers compared to 1.9 years for former smokers and 2.2 years for current smokers. These findings highlight the survival advantage of never smokers over smokers. Similarly, our study found a one-year OS of 61% in never-smokers (vs. 54.8% in light smokers) [14]. A retrospective study of 4,267 patients with stage IV NSCLC found that never smokers had a median OS of 21.1 months, significantly longer than the 15.1 months observed in smokers [15]. Additionally, a large-scale analysis of 30,310 patients with advanced NSCLC reported that EGFR-mutant never-smokers had a median OS of 25.5 months compared with 19.4 months in EGFR-mutant smokers [4]. These findings reinforce our results, demonstrating that never-smokers with EGFR mutations tend to have better survival outcomes than smokers. In our cohort, the 3-year OS was higher for EGFR-negative than EGFR-positive disease in both light smokers (30.0% vs. 4.9%) andnever-smokers (36.5% vs. 2.2%). EGFR mutations were common in our cohort, accounting for 80.6% of light smokers and 58.5% of never-smokers. A study of 673 NSCLC patients found EGFR mutations in 21.5% of never-smokers versus 15.6% of smokers [16], while a 30,310-patient analysis confirmed higher EGFR-mutation rates in never-smokers [17]. Age is also a critical prognostic factor for survival. A study of 4,267 stage IV NSCLC patients showed that 43.2% of younger patients (≤ 50 years) were never smokers, with a median OS of 21.1 months, which was significantly longer than the 15.1 months observed in older patients [15]. Consistent with this pattern, our cohort’s ≤ 46-year subgroup showed markedly better outcomes: light smokers maintained a 100% O at 1, 3, and 5 years, while never-smokers’ OS declined from 67.1% a 1 year to 29.2% a both 3 and 5 years; in contrast, among patients ≥ 60 years old, 5-year OS fell to 0% i light smokers and 14.4% i never-smokers. Performance status is crucial. A cohort of 74 advanced NSCLC patients treated with pembrolizumab found that ECOG PS ≥ 2 predicted markedly worse outcomes (median OS 4.1 months vs. 23.2 months in ECOG 0–1) [18]. Likewise, a retrospective series of 404 NSCLC patients reported that ECOG PS 2 had a disease-control rate of only 21.8% vrsus 50.3% i ECOG 0–1, with OS of 4.0 vs. 13.2 months [19]. In our cohort, ECOG 0 light smokers achieved a 1-year OS of 86.7% versu 78.3% in ECG 0 never-smokers, but only the latter reached a 30.1% 5-yea OS. PD-L1 expression ≥ 49% was present in 30.5% of our sample, closely matching a meta-analysis of 16,486 NSCLC cases, where 23% had TPS ≥ 50% [19]. Patients with high PD-L1 expression generally fare better with ICIs; one study reported a median OS of 33.1 months for PD-L1 ≥ 50% versus 11.8 months for PD-L1 < 1% [20]. Nevertheless, EGFR-positive NSCLC often responds poorly to ICIs because of low PD-L1 levels and an immune-cold microenvironment. A meta-analysis of 247 EGFR-positive patients showed an ORR of only 20.6% [21].Combination regimens (chemotherapy ± targeted agents) can increase disease control rates to 83.3% [22, 23], undrscoring the need for tailored strategies in EGFR-positive disease. The distinct mutational landscape in non-smoking NSCLC highlights the need for molecular profiling and targeted therapies. The IPASS study demonstrated superior outcomes for EGFR-mutant non-smokers treated with first generation TKIs such as gefitinib compared to chemotherapy. In contrast, chemotherapy was better in EGFR-wild-type cases [24]. Similarly, the first SIGNAL trial showed improved median PFS in EGFR-mutant patients receiving TKIs, though median OS benefit was obscured by cross-over to TKIs after chemotherapy failure [25]. However, EGFR-positive cases exhibit prognostic variability based on the mutation subtype and resistance development. EGFR exon 20 insertion showed a significantly poorer response to EGFR-TKIs, whereas exon 19 deletions (median PFS ≈ 12 months) and L858R mutations (median PFS ≈ 8 months) demonstrated better outcomes [26, 27]. Additionally, resistance mutations, such as T790M (present in 50–60% of rsistant cases) and C797S (20–30%), sinificantly compromise survival despite initial favorable responses [28, 29]. For ALK-positive NSCLC, crizotinib was the first TKI to show efficacy, but its limited CNS penetration and resistance curtailed benefit. Alectinib, a second-generation ALK TKI demonstrated superior PFS (34.8 months vs. 10.9 months), OS (62.5% vs. 45.5%), intracranial response rates (81% vs. 50%) and fewer adverse events compared to crizotinib [30]. Lorlatinib, a third-generation ALK TKI, effectively overcomes resistant mutations such as G1202R and penetrates the CNS, though its toxicity profile necessitates careful management [30]. Notably, few trials have specifically assessed ALK inhibitors in non-smoking NSCLC, an area requiring future research. For ROS1-rearranged patients, crizotinib had a 65–72% ORR and median PFS of 15–20 months with a limited efficacy in CNS metastases [30]. In contrast, entrectinib, a more potent TKI with better CNS penetration, demonstrated a 77% ORR and 19-month median PFS, with superior intracranial activity (55% intracranial ORR) [30]. Our study is among the first to analyze never- and light-smokers with stage IV NSCLC in the Middle East, offering region-specific insights from a well-defined cohort with comprehensive molecular profiles. Limitations include the retrospective design and lack of longitudinal resistance data. Another limitation is that survival was measured from the date of treatment initiation rather than from diagnosis. This approach reflects outcomes after treatment but does not represent the entire course of the disease. Confounders such as second-hand smoke exposure, comorbidities, non-brain metastases, and varied treatment modalities were not fully considered. Restricted access to advanced targeted therapies -like osimertinib- during the study period may also have influenced survival outcomes, particularly among never-smokers with EGFR resistant mutations. Multicenter studies with larger cohorts are warranted to validate and extend these findings. Conclusion Never smokers and light smokers with stage IV NSCLC in Jordan exhibit unique clinical and molecular signatures, most notably a high burden of EGFR mutations, and divergent survival patterns. Younger age and good performance status coincided with the most favorable long-term outcomes, whereas EGFR-positive disease correlated with earlier progression and cancer-specific mortality despite the availability of targeted therapy raising the concern regarding the developing resistance toward such drugs. Although univariate analyses did not isolate independent prognostic factors, the findings reinforce routine, comprehensive molecular profiling and the pursuit of individualized regimens, such as next-generation EGFR inhibitors, resistance-modifying combinations, or clinical-trial enrollment, to extend survival in these understudied populations. Multicenter Middle Eastern cohorts are needed to validate and refine treatment algorithms for never- and light-smoking patients with advanced NSCLC. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2. Supplementary Material 3. Supplementary Material 3.